Schizophrenia Trial, Recruiting (NCT06123897)

Schizophrenia Trial, Recruiting NCT06123897 Sponsor: Central South University Condition: Schizophrenia

Printed from Voxsanity (voxsanity.com.au) — NCT06123897 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Schizophrenia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been clinically diagnosed with schizophrenia according to the ICD-11 diagnostic system.
People whose schizophrenia diagnosis has been confirmed through a structured research interview called the SCID-5-RV.

Who may not be able to join:

People whose clinical assessment confirms a diagnosis of certain neurodevelopmental conditions, bipolar disorder or related conditions, or substance use disorders (note: alcohol and tobacco use are not listed as reasons for exclusion — confirm with trial site).
People who have serious or sudden-onset physical health conditions, such as traumatic brain injury, brain tumours or brain infections, acute heart conditions, acute breathing/lung conditions, or acute blood disorders.
People who have a clearly identified genetic condition, such as tuberous sclerosis, multiple sclerosis, Kleefstra syndrome, 22q11.2 deletion syndrome, Prader-Willi syndrome, Klinefelter syndrome (47,XXY), or similar conditions.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Renrong Wu, M.D., Ph.D., Mental Health Institute of Second Xiangya Hospital,CSU

Phone: 15874179855

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06123897

Sponsor: Central South University

Phase: Not Applicable

Status: Recruiting

Condition: Schizophrenia

Trial contact: 15874179855

More information: https://clinicaltrials.gov/study/NCT06123897

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been clinically diagnosed with schizophrenia according to the ICD-11 diagnostic system.
People whose schizophrenia diagnosis has been confirmed through a structured research interview called the SCID-5-RV.

Who may not be able to join:

People whose clinical assessment confirms a diagnosis of certain neurodevelopmental conditions, bipolar disorder or related conditions, or substance use disorders (note: alcohol and tobacco use are not listed as reasons for exclusion — confirm with trial site).
People who have serious or sudden-onset physical health conditions, such as traumatic brain injury, brain tumours or brain infections, acute heart conditions, acute breathing/lung conditions, or acute blood disorders.
People who have a clearly identified genetic condition, such as tuberous sclerosis, multiple sclerosis, Kleefstra syndrome, 22q11.2 deletion syndrome, Prader-Willi syndrome, Klinefelter syndrome (47,XXY), or similar conditions.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Central South University

Registry

ClinicalTrials.gov

Start date

1 January 2024

Est. completion

1 July 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change of the MATRICS Consensus Cognitive Battery score; Change of clinical symptoms by Positive And Negative Syndrome Scale; Change of clinical symptoms by Clinical Global Impression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov